MAP2K7 and neoplasm: Vemurafenib resulted in tumor regression in the majority (14 of 19) of NSCLC patients, and the objective response rate was 42%.107 In a phase 2 trial, dabrafenib treatment with trametinib, a MEK inhibitor, reached 63% overall response in BRAF V600E-mutant NSCLC patients, who had documented tumor progression after previous platinum-based chemotherapy.108